We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity.
- Authors
Calhoun R; Jablons D; Lau D; Gandara DR
- Abstract
While 5-year survival rates in patients with stage IB non-small-cell lung cancer (NSCLC) are historically modest (40% to 67%), adjuvant chemotherapy trials including this subgroup have shown little evidence of chemotherapeutic benefit. This article reviews the available data regarding adjuvant chemotherapy following surgically resected stage IB NSCLC, framed within the context of present and future proposed definitions of this diagnosis. The discussion addresses limitations of the current staging system and how this contributes to the mixed results seen with adjuvant treatment. In addition, the authors consider current treatment options for stage IB NSCLC and review planned clinical trials for stage I disease designed to exploit new pharmacogenomic findings.
- Publication
Oncology (08909091), 2008, Vol 22, Issue 5, p511
- ISSN
0890-9091
- Publication type
Journal Article